drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A subcutaneously administered bispecific antibody immunotherapy that binds CD20 on malignant B cells and an additional immune-effector target to redirect immune cell–mediated cytotoxicity for B-cell depletion in relapsed/refractory CD20+ B-cell non-Hodgkin lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Subcutaneously administered bispecific antibody that binds CD20 on malignant B cells and a T‑cell effector target to recruit and activate T cells, forming an immune synapse and redirecting T‑cell–mediated cytotoxicity to deplete CD20+ B cells in relapsed/refractory non‑Hodgkin lymphoma.
drug_name
SCTB35
nct_id_drug_ref
NCT06318884